Skip to main content
SpringerLink
Log in
Book cover

Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures pp 407–435Cite as

Current Status of BoneMarrow Transplantation for Treatment of Cancer

  • Chapter
  • First Online:

  • 1137 Accesses

Part of the book series: Cancer Growth and Progression ((CAGP,volume 13))

Abstract

Cancer treatment is evolving and improving through a better understanding of molecular biology and the identification of specific cancer-associated targets. However, most cancer therapies depend on cytotoxic chemicals that are marginally more toxic to neoplastic cells than normal cells. Thus, cancer therapy is imperfect, toxic, and curative in only a small percentage of patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Akpek G, Ambinder RF, Piantadosi S et al (2001) Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol 19:4314–4321

    CAS  PubMed  Google Scholar 

  2. Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330:484–489

    Article  CAS  PubMed  Google Scholar 

  3. Anderson JE, Litzow MR, Appelbaum FR et al (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol 11:2342–2350

    CAS  PubMed  Google Scholar 

  4. Appelbaum FR (2004) Allogeneic transplantation for chronic myeloid leukemia. Thomas’ hematopoietic cell transplantation, vol 457, section 5, ch. 73. Wiley-Blackwell, Hoboken, NJ, pp 1007–1017

    Google Scholar 

  5. Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411:385–389

    Article  CAS  PubMed  Google Scholar 

  6. Appelbaum FR, Dahlberg S, Thomas ED et al (1984) Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Int Med 101:581–588

    CAS  PubMed  Google Scholar 

  7. Appelbaum FR, Fisher LD, Thomas ED (1988) Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. Blood 72:179–184

    CAS  PubMed  Google Scholar 

  8. Attal M, Blaise D, Marit G et al (1995) Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group Blood 86: 1619–1628

    CAS  Google Scholar 

  9. Attal M, Harousseau JL, Facon T et al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495–2502

    Article  CAS  PubMed  Google Scholar 

  10. Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335: 91–97

    Article  CAS  PubMed  Google Scholar 

  11. Aversa F, Tabilio A, Velardi A et al (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339:1186–1193

    Article  CAS  PubMed  Google Scholar 

  12. Badros A, Barlogie B, Siegel E et al (2002) Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 20:1295–1303

    Article  PubMed  Google Scholar 

  13. Barlogie B, Jagannath S, Dixon DO et al (1990) High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 76:677–680

    CAS  PubMed  Google Scholar 

  14. Bashey A, Corringham S, Gilpin E et al (2000) Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation. Cytotherapy 2:195–200

    Article  CAS  PubMed  Google Scholar 

  15. Bender JG, To LB, Williams S et al (1992) Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1:329–341

    CAS  PubMed  Google Scholar 

  16. Bensinger WI, Martin PJ, Storer B et al (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344: 175–181

    Article  CAS  PubMed  Google Scholar 

  17. Bensinger WI, Weaver CH, Appelbaum FR et al (1995) Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85:1655–1658

    CAS  PubMed  Google Scholar 

  18. Beyer J, Kramar A, Mandanas R et al (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14:2638–2645

    CAS  PubMed  Google Scholar 

  19. Beyer J, Stenning S, Gerl A et al (2002) High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 13:599–605

    Article  CAS  PubMed  Google Scholar 

  20. Bierman PJ, Sweetenham JW, Loberiza FR Jr et al (2003) Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin’s lymphoma: a comparison with allogeneic and autologous transplantation – The lymphoma working committee of the international bone marrow transplant registry and the European group for blood and marrow transplantation. J Clin Oncol 21:3744–3753

    Article  PubMed  Google Scholar 

  21. Blade J, San Miguel JF, Fontanillas M et al (2001) Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J 2:272–278

    Article  CAS  PubMed  Google Scholar 

  22. Bloomfield CD, Lawrence D, Byrd JC et al (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173–4179

    CAS  PubMed  Google Scholar 

  23. Blume KG, Forman SJ, Nademanee AP et al (1986) Bone marrow transplantation for hematologic malignancies in patients aged 30 years or older. J Clin Oncol 4:1489–1492

    CAS  PubMed  Google Scholar 

  24. Boeve S, Strupeck J, Creech S et al (2004) Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 33:997–1003

    Article  CAS  PubMed  Google Scholar 

  25. Bokemeyer C, Kollmannsberger C, Meisner C et al (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17:3450–3456

    CAS  PubMed  Google Scholar 

  26. Bokemeyer C, Schleucher N, Metzner B et al (2003) First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer 89:29–35

    Article  CAS  PubMed  Google Scholar 

  27. Bregni M, Dodero A, Peccatori J et al (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99:4234–4236

    Article  CAS  PubMed  Google Scholar 

  28. Bruno B, Rotta M, Patriarca F et al (2007) A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356:1110–1120

    Article  CAS  PubMed  Google Scholar 

  29. Buckner CD, Clift RA, Thomas ED et al (1982) Allogeneic marrow transplantation for patients with acute non-lymphoblastic leukemia in second remission. Leuk Res 6:395–399

    Article  CAS  PubMed  Google Scholar 

  30. Cahn JY, Labopin M, Sierra J et al (2000) No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute leukaemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110:308–314

    Article  CAS  PubMed  Google Scholar 

  31. Cassileth PA, Harrington DP, Appelbaum FR et al (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339:1649–1656

    Article  CAS  PubMed  Google Scholar 

  32. Cavins JA, Scheer SC, Thomas ED et al (1964) The recovery of lethally irradiated dogs given infusions of autologous leukocytes preserved at −80°C. Blood 23: 38–42

    CAS  PubMed  Google Scholar 

  33. Chalandon Y, Barnett MJ, Horsman DE et al (2002) Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 8:435–443

    Article  PubMed  Google Scholar 

  34. Chen L, Widhopf G, Huynh L et al (2002) Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100:4609–4614

    Article  CAS  PubMed  Google Scholar 

  35. Chevreau C, Droz JP, Pico JL et al (1993) Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol 23:213–217, discussion 8

    CAS  PubMed  Google Scholar 

  36. Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348: 1875–1883

    Article  CAS  PubMed  Google Scholar 

  37. Childs R, Chernoff A, Contentin N et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750–788

    Article  CAS  PubMed  Google Scholar 

  38. Chopra R, Goldstone AH, Pearce R et al (1992) Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: a case-controlled analysis of the European bone marrow transplant group registry data. J Clin Oncol 10:1690–1695

    CAS  PubMed  Google Scholar 

  39. Clift RA, Buckner CD, Thomas ED et al (1994) Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 84:4368–4373

    CAS  PubMed  Google Scholar 

  40. Clift RA, Buckner CD, Thomas ED et al (1987) The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 2:243–258

    CAS  PubMed  Google Scholar 

  41. Clift RA, Radich J, Appelbaum FR et al (1999) Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 94:3960–3962

    CAS  PubMed  Google Scholar 

  42. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    Article  CAS  PubMed  Google Scholar 

  43. Collins RH Jr, Shpilberg O, Drobyski WR et al (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433–444

    PubMed  Google Scholar 

  44. Copelan EA, Biggs JC, Thompson JM et al (1991) Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 78:838–843

    CAS  PubMed  Google Scholar 

  45. Cornelissen JJ, Carston M, Kollman C et al (2001) Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 97:1572–1577

    Article  CAS  PubMed  Google Scholar 

  46. Cottler-Fox MH, Lapidot T, Petit I et al (2003) Stem cell mobilization. Hematology Am Soc Hematol Educ Program 1:419–437

    Google Scholar 

  47. Couban S, Simpson DR, Barnett MJ et al (2002) A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100:1525–1531

    Article  CAS  PubMed  Google Scholar 

  48. Crespo M, Bosch F, Villamor N et al (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764–1775

    Article  CAS  PubMed  Google Scholar 

  49. Decatris MP, Wilkinson PM, Welch RS et al (2000) High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann Oncol 11:427–434

    Article  CAS  PubMed  Google Scholar 

  50. Devine SM, Flomenberg N, Vesole DH et al (2004) Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J Clin Oncol 22:1095–1102

    Article  CAS  PubMed  Google Scholar 

  51. Doney K, Hagglund H, Leisenring W et al (2003) Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant 9:472–481

    Article  PubMed  Google Scholar 

  52. Dreger P, Brand R, Hansz J et al (2003) Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 17:841–848

    Article  CAS  PubMed  Google Scholar 

  53. Dreger P, Stilgenbauer S, Benner A et al (2004) The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 103:2850–2858

    Article  CAS  PubMed  Google Scholar 

  54. Droz JP, Pico JL, Ghosn M et al (1991) Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer. Eur J Cancer 27:831–835

    Article  CAS  PubMed  Google Scholar 

  55. Einhorn LH, Williams SD, Chamness A et al (2007) High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357:340–348

    Article  CAS  PubMed  Google Scholar 

  56. Enright H, Daniels K, Arthur DC et al (1996) Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. Bone Marrow Transplant 17:537–542

    CAS  PubMed  Google Scholar 

  57. Esteve J, Villamor N, Colomer D et al (2002) Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Blood 99:1873–1874

    Article  PubMed  Google Scholar 

  58. Faderl S, Jeha S, Kantarjian HM (2003) The biology and therapy of adult acute lymphoblastic leukemia. Cancer 98:1337–1354

    Article  PubMed  Google Scholar 

  59. Fais F, Ghiotto F, Hashimoto S et al (1998) Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102:1515–1525

    Article  CAS  PubMed  Google Scholar 

  60. Federico M, Bellei M, Brice P et al (2003) High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. J Clin Oncol 21:2320–2325

    Article  CAS  PubMed  Google Scholar 

  61. Fermand JP, Brechignac S (1999) The role of autologous stem cell transplantation in the management of multiple myeloma. Pathol Biol (Paris) 47:199–202

    CAS  Google Scholar 

  62. Fermand JP, Ravaud P, Chevret S et al (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131–3136

    CAS  PubMed  Google Scholar 

  63. Ferrant A, Labopin M, Frassoni F et al (1997) Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European group for blood and marrow transplantation study. Acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Blood 90:2931–2938

    CAS  PubMed  Google Scholar 

  64. Flowers ME, Parker PM, Johnston LJ et al (2002) Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100:415–419

    Article  CAS  PubMed  Google Scholar 

  65. Freedman AS, Neuberg D, Mauch P et al (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325–3333

    CAS  PubMed  Google Scholar 

  66. Gale RP, Horowitz MM, Rees JK et al (1996) Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 10:13–19

    CAS  PubMed  Google Scholar 

  67. Gale RP, Horowitz MM, Weiner RS et al (1995) Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 16:203–208

    CAS  PubMed  Google Scholar 

  68. Gaziev D, Galimberti M, Polchi P et al (2002) Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results. Bone Marrow Transplant 29:1–8

    Article  CAS  PubMed  Google Scholar 

  69. Gianni AM, Bregni M, Siena S et al (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290–1297

    Article  CAS  PubMed  Google Scholar 

  70. Giralt S, Hester J, Huh Y et al (1995) CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337–4343

    CAS  PubMed  Google Scholar 

  71. Gisselbrecht C, Lepage E, Molina T et al (2002) Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472–2479

    Article  CAS  PubMed  Google Scholar 

  72. Glass B, Nickelsen M, Dreger P et al (2004) Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect. Bone Marrow Transplant 34:391–397

    Article  CAS  PubMed  Google Scholar 

  73. Goldman JM, Gale RP, Horowitz MM et al (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Int Med 108: 806–814

    CAS  PubMed  Google Scholar 

  74. Goldstone AH, Richards SM, Lazarus HM et al (2008) In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the international ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111: 1827–1833

    Article  CAS  PubMed  Google Scholar 

  75. Gratwohl A, Hermans J, van Biezen A et al (1996) Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic leukaemia working party of the European group for blood and marrow transplantation (EBMT). Br J Haematol 95:494–500

    Article  CAS  PubMed  Google Scholar 

  76. Grimwade D, Walker H, Oliver F et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children’s leukaemia working parties. Blood 92:2322–2333

    CAS  PubMed  Google Scholar 

  77. Gutierrez-Delgado F, Bensinger W (2001) Safety of granulocyte colony-stimulating factor in normal donors. Curr Opin Hematol 8:155–160

    Article  CAS  PubMed  Google Scholar 

  78. Haioun C, Lepage E, Gisselbrecht C et al (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87–2 protocol – a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 18:3025–3030

    CAS  PubMed  Google Scholar 

  79. Hammert LC, Ball ED (1997) Purging marrow or peripheral blood stem cells for autografting. Curr Opin Hematol 4:423–428

    Article  CAS  PubMed  Google Scholar 

  80. Hansen JA, Gooley TA, Martin PJ et al (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962–968

    Article  CAS  PubMed  Google Scholar 

  81. Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie house, Virginia, November 1997. J Clin Oncol 17:3835–3849

    CAS  PubMed  Google Scholar 

  82. Harris NL, Jaffe ES, Stein H et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 84:1361–1392

    CAS  PubMed  Google Scholar 

  83. Harstrick A, Schmoll HJ, Wilke H et al (1991) Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 9:1549–1555

    CAS  PubMed  Google Scholar 

  84. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease: international prognostic factors project on advanced Hodgkin’s disease. N Engl J Med 339:1506–1514

    Article  CAS  PubMed  Google Scholar 

  85. Helg C, Starobinski M, Jeannet M et al (1998) Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 29:301–313

    Article  CAS  PubMed  Google Scholar 

  86. Henslee-Downey PJ, Parrish RS, MacDonald JS et al (1996) Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation 61:738–745

    Article  CAS  PubMed  Google Scholar 

  87. Hoelzer D (1992) Prognostic factors in acute lymphoblastic leukemia. Leukemia 6(Suppl 4):49–51

    PubMed  Google Scholar 

  88. Hoelzer D, Ludwig WD, Thiel E et al (1996) Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87:495–508

    CAS  PubMed  Google Scholar 

  89. Horowitz MM, Gale RP, Sondel PM et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555–562

    CAS  PubMed  Google Scholar 

  90. International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594–603

    Google Scholar 

  91. Johnson TA, Rassenti LZ, Kipps TJ (1997) Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 158:235–246

    CAS  PubMed  Google Scholar 

  92. Jones RJ, Ambinder RF, Piantadosi S et al (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649–653

    CAS  PubMed  Google Scholar 

  93. Jung AS, Holman PR, Castro JE et al (2009) Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia. Biol Blood Marrow Transplant 15:1306–1313

    Article  CAS  PubMed  Google Scholar 

  94. Junghanss C, Boeckh M, Carter RA et al (2002) Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99:1978–1985

    Article  CAS  PubMed  Google Scholar 

  95. Keating MJ, Chiorazzi N, Messmer B et al (2003) Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 153–175

    Google Scholar 

  96. Keating MJ, Smith TL, Kantarjian H et al (1988) Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 2:403–412

    CAS  PubMed  Google Scholar 

  97. Kebriaei P, Larson RA (2003) Progress and challenges in the therapy of adult acute lymphoblastic leukemia. Curr Opin Hematol 10:284–289

    Article  PubMed  Google Scholar 

  98. Khouri IF, Champlin RE (2004) Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 31:22–26

    Article  PubMed  Google Scholar 

  99. Khouri IF, Keating MJ, Saliba RM et al (2002) Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4:217–221

    Article  CAS  PubMed  Google Scholar 

  100. Khouri IF, Keating MJ, Vriesendorp HM et al (1994) Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 12:748–758

    CAS  PubMed  Google Scholar 

  101. Khouri IF, McLaughlin P, Saliba RM et al (2008) Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111:5530–5536

    Article  CAS  PubMed  Google Scholar 

  102. Khouri IF, Saliba RM, Giralt SA et al (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98:3595–3599

    Article  CAS  PubMed  Google Scholar 

  103. Klingemann HG, Storb R, Fefer A et al (1986) Bone marrow transplantation in patients aged 45 years and older. Blood 67:770–776

    CAS  PubMed  Google Scholar 

  104. Kolb HJ, Mittermuller J, Clemm C et al (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465

    CAS  PubMed  Google Scholar 

  105. Kolb HJ, Schattenberg A, Goldman JM et al (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041–2050

    CAS  PubMed  Google Scholar 

  106. Kollmannsberger C, Nichols C, Meisner C et al (2000) Identification of prognostic subgroups among patients with metastatic ‘IGCCCG poor-prognosis’ germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol 11:1115–1120

    Article  CAS  PubMed  Google Scholar 

  107. Korbling M, Przepiorka D, Huh YO et al (1995) Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 85:1659–1665

    CAS  PubMed  Google Scholar 

  108. Kurtzberg J, Martin P, Chao N et al (2000) Unrelated placental blood in marrow transplantation. Stem Cells 18:153–154

    Article  CAS  PubMed  Google Scholar 

  109. Lane TA, Bashey A, Carrier E et al (2004) Improving the efficiency of PBPC collection by pre-apheresis peripheral blood and mid-apheresis product measurements of CD34 cells. Cytotherapy 6:318–327

    Article  CAS  PubMed  Google Scholar 

  110. Lane TA, Law P, Maruyama M et al (1995) Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 85:275–282

    CAS  PubMed  Google Scholar 

  111. Laport GF, Larson RA (1997) Treatment of adult acute lymphoblastic leukemia. Semin Oncol 24:70–82

    CAS  PubMed  Google Scholar 

  112. Laughlin MJ, Barker J, Bambach B et al (2001) Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344:1815–1822

    Article  CAS  PubMed  Google Scholar 

  113. Lemoli RM, de Vivo A, Damiani D et al (2003) Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. Blood 102:1595–1600

    Article  CAS  PubMed  Google Scholar 

  114. Lie AK, Hui CH, Rawling T et al (1998) Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Bone Marrow Transplant 22:853–857

    Article  CAS  PubMed  Google Scholar 

  115. Linch DC, Goldstone AH (1999) High-dose therapy for Hodgkin’s disease. Br J Haematol 107:685–690

    Article  CAS  PubMed  Google Scholar 

  116. Loehrer PJ Sr, Lauer R, Roth BJ et al (1988) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Int Med 109:540–546

    PubMed  Google Scholar 

  117. Lokhorst HM, Wu K, Verdonck LF et al (2004) The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 103:4362–4364

    Article  CAS  PubMed  Google Scholar 

  118. Makita K, Ohta K, Mugitani A et al (2004) Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 33:661–665

    Article  CAS  PubMed  Google Scholar 

  119. Maloney DG, Molina AJ, Sahebi F et al (2003) Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102:3447–3454

    Article  CAS  PubMed  Google Scholar 

  120. Marafioti T, Hummel M, Foss HD et al (2000) Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 95:1443–1450

    CAS  PubMed  Google Scholar 

  121. Mayer RJ, Davis RB, Schiffer CA et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia: cancer and leukemia Group B. N Engl J Med 331:896–903

    Article  CAS  PubMed  Google Scholar 

  122. McElwain TJ, Powles RL (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2:822–824

    Article  CAS  PubMed  Google Scholar 

  123. McGlave PB, Haake RJ, Bostrom BC et al (1988) Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood 72:1512–1517

    CAS  PubMed  Google Scholar 

  124. McGlave PB, Shu XO, Wen W et al (2000) Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years’ experience of the national marrow donor program. Blood 95:2219–2225

    CAS  PubMed  Google Scholar 

  125. McSweeney PA, Niederwieser D, Shizuru JA et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97: 3390–3400

    Article  CAS  PubMed  Google Scholar 

  126. Meisenberg B, Brehm T, Schmeckel A et al (1998) A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells. Transfusion 38:209–215

    Article  CAS  PubMed  Google Scholar 

  127. Michallet M, Carraras E, Cornelissen JJ et al (1999) Allotransplants and autotransplants in CLL. Bone Marrow Transplant 23(Suppl 1):S53

    Google Scholar 

  128. Mielcarek M, Martin PJ, Leisenring W et al (2003) Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102:756–62

    Article  CAS  PubMed  Google Scholar 

  129. Mohle R, Pforsich M, Fruehauf S et al (1994) Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis. Bone Marrow Transplant 14:827–832

    CAS  PubMed  Google Scholar 

  130. Moreau P, Facon T, Attal M et al (2002) Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99:731–735

    Article  CAS  PubMed  Google Scholar 

  131. Moreau P, Fiere D, Bezwoda WR et al (1997) Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol 15:660–666

    CAS  PubMed  Google Scholar 

  132. Nash RA, Antin JH, Karanes C et al (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96:2062–2068

    CAS  PubMed  Google Scholar 

  133. Nichols CR, Andersen J, Lazarus HM et al (1992) High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern cooperative oncology group protocol. J Clin Oncol 10:558–563

    CAS  PubMed  Google Scholar 

  134. Nichols CR, Tricot G, Williams SD et al (1989) Dose-intensive chemotherapy in refractory germ cell cancer – a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932–939

    CAS  PubMed  Google Scholar 

  135. Nieto Y (2003) The verdict is not in yet: analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica 88:201–211

    CAS  PubMed  Google Scholar 

  136. O’Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004

    Article  PubMed  Google Scholar 

  137. Passweg JR, Tiberghien P, Cahn JY et al (1998) Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 21:153–158

    Article  CAS  PubMed  Google Scholar 

  138. Pavletic ZS, Arrowsmith ER, Bierman PJ et al (2000) Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 25:717–722

    Article  CAS  PubMed  Google Scholar 

  139. Pavletic ZS, Bierman PJ, Vose JM et al (1998) High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol 9:1023–1026

    Article  CAS  PubMed  Google Scholar 

  140. Peggs KS, Mackinnon S (2001) Cellular therapy: donor lymphocyte infusion. Curr Opin Hematol 8:349–354

    Article  CAS  PubMed  Google Scholar 

  141. Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333: 1540–1545

    Article  CAS  PubMed  Google Scholar 

  142. Porter DL, Roth MS, McGarigle C et al (1994) Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100–106

    Article  CAS  PubMed  Google Scholar 

  143. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994

    Article  Google Scholar 

  144. Provan D, Bartlett-Pandite L, Zwicky C et al (1996) Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88:2228–2235

    CAS  PubMed  Google Scholar 

  145. Pui CH, Relling MV, Downing JR (2004) Acute lymphoblastic leukemia. N Engl J Med 350:1535–1548

    Article  CAS  PubMed  Google Scholar 

  146. Rabinowe SN, Soiffer RJ, Gribben JG et al (1993) Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 82:1366–1376

    CAS  PubMed  Google Scholar 

  147. Radich JP, Gehly G, Gooley T et al (1995) Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 85:2632–2638

    CAS  PubMed  Google Scholar 

  148. Radich JP, Gooley T, Bensinger W et al (2003) HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 102:31–35

    Article  CAS  PubMed  Google Scholar 

  149. Rajkumar SV, Fonseca R, Lacy MQ et al (1999) Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 23: 1267–1272

    Article  CAS  PubMed  Google Scholar 

  150. Ratanatharathorn V, Uberti J, Karanes C et al (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphoma. Blood 84:1050–1055

    CAS  PubMed  Google Scholar 

  151. Ringden O, Horowitz MM, Gale RP et al (1993) Outcome after allogeneic bone marrow transplant for leukemia in older adults. Jama 270:57–60

    Article  CAS  PubMed  Google Scholar 

  152. Rini BI, Zimmerman T, Stadler WM et al (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20:2017–2024

    Article  PubMed  Google Scholar 

  153. Roche H, Viens P, Biron P et al (2003) High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10:42–47

    PubMed  Google Scholar 

  154. Rodenhuis S, Bontenbal M, Beex LV et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349:7–16

    Article  CAS  PubMed  Google Scholar 

  155. Rondon G, Giralt S, Huh Y et al (1996) Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18:669–672

    CAS  PubMed  Google Scholar 

  156. Rosenwald A, Alizadeh AA, Widhopf G et al (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194:1639–1647

    Article  CAS  PubMed  Google Scholar 

  157. Rosinol L, Perez-Simon JA, Sureda A et al (2008) A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112:3591–3593

    Article  CAS  PubMed  Google Scholar 

  158. Roush KS, Hillyer CD (2002) Donor lymphocyte infusion therapy. Transfus Med Rev 16:161–176

    Article  PubMed  Google Scholar 

  159. Rowley SD, Donaldson G, Lilleby K et al (2001) Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 97:2541–2548

    Article  CAS  PubMed  Google Scholar 

  160. Rubinstein P, Carrier C, Scaradavou A et al (1998) Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 339: 1565–1577

    Article  CAS  PubMed  Google Scholar 

  161. Ruggeri L, Capanni M, Urbani E et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097–2100

    Article  CAS  PubMed  Google Scholar 

  162. Sawyers CL, Hochhaus A, Feldman E et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530–3539

    Article  CAS  PubMed  Google Scholar 

  163. Schetelig J, Thiede C, Bornhauser M et al (2003) Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the cooperative German transplant study group. J Clin Oncol 21: 2747–2753

    Article  CAS  PubMed  Google Scholar 

  164. Schiller G, Feig SA, Territo M et al (1994) Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol 88:72–78

    Article  CAS  PubMed  Google Scholar 

  165. Schlenk RF, Dohner K, Krauter J et al (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909–1918

    Article  CAS  PubMed  Google Scholar 

  166. Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359: 2065–2071

    Article  CAS  PubMed  Google Scholar 

  167. Schouten HC, Qian W, Kvaloy S et al (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 21:3918–3927

    Article  CAS  PubMed  Google Scholar 

  168. Selby PJ, McElwain TJ, Nandi AC et al (1987) Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 66:55–62

    CAS  PubMed  Google Scholar 

  169. Sierra J, Storer B, Hansen JA et al (2000) Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 26:397–404

    Article  CAS  PubMed  Google Scholar 

  170. Slovak ML, Kopecky KJ, Cassileth PA et al (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest oncology group/Eastern cooperative oncology group study. Blood 96:4075–4083

    CAS  PubMed  Google Scholar 

  171. Stadtmauer EA, O’Neill A, Goldstein LJ et al (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer: Philadelphia bone marrow transplant group. N Engl J Med 342:1069–1076

    Article  CAS  PubMed  Google Scholar 

  172. Stewart AK, Vescio R, Schiller G et al (2001) Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 19:3771–3779

    CAS  PubMed  Google Scholar 

  173. Stiff P, Micallef I, McCarthy P et al (2009) Treatment with plerixafor in non-Hodgkin’s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 15:249–256

    Article  CAS  PubMed  Google Scholar 

  174. Stockerl-Goldstein KE, Reddy SA, Horning SF et al (2000) Favorable treatment outcome in non-Hodgkin’s lymphoma patients with “poor” mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 6:506–512

    Article  CAS  PubMed  Google Scholar 

  175. Storb R (2003) Allogeneic hematopoietic stem cell transplantation – yesterday, today, and tomorrow. Exp Hematol 31:1–10

    Article  PubMed  Google Scholar 

  176. Storb R, Deeg HJ, Farewell V et al (1986) Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68:119–125

    CAS  PubMed  Google Scholar 

  177. Storb R, Deeg HJ, Whitehead J et al (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314: 729–735

    Article  CAS  PubMed  Google Scholar 

  178. Storb R, Raff RF, Appelbaum FR et al (1993) FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. Transplantation 56:800–807

    Article  CAS  PubMed  Google Scholar 

  179. Storb R, Yu C, Barnett T et al (1999) Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 94:1131–1136

    CAS  PubMed  Google Scholar 

  180. Storb R, Yu C, Wagner JL et al (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048–3054

    CAS  PubMed  Google Scholar 

  181. Storb R, Yu C, Zaucha JM et al (1999) Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 94:2523–2529

    CAS  PubMed  Google Scholar 

  182. Storek J, Dawson MA, Storer B et al (2001) Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 97:3380–3389

    Article  CAS  PubMed  Google Scholar 

  183. Suciu S, Mandelli F, de Witte T et al (2003) Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102: 1232–1240

    Article  CAS  PubMed  Google Scholar 

  184. Sureda A, Robinson S, de Elvira C et al (2003) Non myeloablative allogeneic stem cell transplantation significantly reduces transplant related mortality in comparison with conventional allogeneic transplantation in relapsed or refractory hodgkin’s disease: results of the European group for blood and marrow transplantation for the EBMT lymphoma working party.

    Google Scholar 

  185. Tallman MS, Kopecky KJ, Amos D et al (1989) Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. J Clin Oncol 7:326–337

    CAS  PubMed  Google Scholar 

  186. Tallman MS, Rowlings PA, Milone G et al (2000) Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 96:1254–1258

    CAS  PubMed  Google Scholar 

  187. Talpaz M, Silver RT, Druker BJ et al (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928–1937

    Article  CAS  PubMed  Google Scholar 

  188. Tartarone A, Romano G, Galasso R et al (2003) Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data. Bone Marrow Transplant 31:525–530

    Article  CAS  PubMed  Google Scholar 

  189. Thomas ED, Buckner CD, Clift RA et al (1979) Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 301:597–599

    Article  CAS  PubMed  Google Scholar 

  190. Thomas ED, Kasakura S, Cavins JA et al (1963) Marrow transplants in lethally irradiated dogs: the effect of Methotrexate on survival of the host and the homograft. Transplantation 1:571–574

    Article  CAS  PubMed  Google Scholar 

  191. Thomas ED, Lochte HL Jr, Cannon JH et al (1959) Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 38:1709–1716

    Article  CAS  PubMed  Google Scholar 

  192. Thomas ED, Sanders JE, Flournoy N et al (1979) Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood 54:468–476

    CAS  PubMed  Google Scholar 

  193. Tricot G, Jagannath S, Vesole D et al (1995) Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588–596

    CAS  PubMed  Google Scholar 

  194. van Besien K, Keralavarma B, Devine S et al (2001) Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia 15:1317–1325

    Article  PubMed  CAS  Google Scholar 

  195. Verdonck LF (1999) Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma: updated results of the Utrecht experience. Leuk Lymphoma 34:129–136

    CAS  PubMed  Google Scholar 

  196. Verdonck LF, van Putten WL, Hagenbeek A et al (1995) Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med 332:1045–1051

    Article  CAS  PubMed  Google Scholar 

  197. Visani G, Rosti G, Bandini G et al (2000) Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol 109:722–728

    Article  CAS  PubMed  Google Scholar 

  198. Vose JM, Sharp G, Chan WC et al (2002) Autologous transplantation for aggressive non-Hodgkin’s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 20:2344–2352

    Article  PubMed  Google Scholar 

  199. Weissinger F, Sandmaier BM, Maloney DG et al (2001) Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 98:3584–3588

    Article  CAS  PubMed  Google Scholar 

  200. Woolfrey E, Nash RA, Sanders JE et al (2000) A non-myeloablative regimen for induction of multi-lineage hematopoietic mixed donor-host chimerism in nonmalignant disorders (abstract). Blood 98:784a

    Google Scholar 

  201. Zittoun RA, Mandelli F, Willemze R et al (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European organization for research and treatment of cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) leukemia cooperative groups. N Engl J Med 332:217–223

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Moores UCSD Cancer Center, La Jolla, CA, 92093-0960, USA

    Edward D. Ball, Asad Bashey, Januario E. Castro & Peter Holman

  2. Moores UCSD Cancer Center, San Diego, CA, USA

    Ewa Carrier

  3. UCSD Transfusion Services and Stem Cell Processing Lab, Moores UCSD Cancer Center, La Jolla, CA, 92093-0960, USA

    Thomas A. Lane

Authors
  1. Edward D. Ball
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Asad Bashey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ewa Carrier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Januario E. Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Holman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas A. Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward D. Ball .

Editor information

Editors and Affiliations

  1. Moores UCSD Cancer Center, 3855 Health Sciences Drive 0820, La Jolla, 92093-0820, California, USA

    Boris R. Minev

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Ball, E.D., Bashey, A., Carrier, E., Castro, J.E., Holman, P., Lane, T.A. (2011). Current Status of BoneMarrow Transplantation for Treatment of Cancer. In: Minev, B. (eds) Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Cancer Growth and Progression, vol 13. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9704-0_23

Download citation

  • DOI: https://doi.org/10.1007/978-90-481-9704-0_23

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-9703-3

  • Online ISBN: 978-90-481-9704-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation